Price Action Report: What’s Ahead for Delcath Systems, Inc. After Today’s Significant Increase?

Price Action Report: What's Ahead for Delcath Systems, Inc. After Today's Significant Increase?

The stock of Delcath Systems, Inc. (NASDAQ:DCTH) is a huge mover today! The stock increased 1.82% or $0.05 on October 3, hitting $2.52. About 88,267 shares traded hands or 222.04% up from the average. Delcath Systems, Inc. (NASDAQ:DCTH) has declined 44.64% since February 29, 2016 and is downtrending. It has underperformed by 56.86% the S&P500.
The move comes after 5 months positive chart setup for the $2.75 million company. It was reported on Oct, 4 by We have $6.78 PT which if reached, will make NASDAQ:DCTH worth $4.65M more.

Analysts await Delcath Systems, Inc. (NASDAQ:DCTH) to report earnings on November, 8.

According to Zacks Investment Research, “Delcath Systems, Inc. has developed a system, the Delcath system, to isolate the liver from the general circulatory system and to administer chemotherapy and other therapeutic agents directly to the liver.”

Insitutional Activity: The institutional sentiment decreased to 1.13 in Q2 2016. Its down 0.30, from 1.43 in 2016Q1. The ratio dived, as 7 funds sold all Delcath Systems, Inc. shares owned while 1 reduced positions. 2 funds bought stakes while 7 increased positions. They now own 1.85 million shares or 18.13% less from 2.26 million shares in 2016Q1.
Barclays Public Ltd Company has invested 0% of its portfolio in Delcath Systems, Inc. (NASDAQ:DCTH). Moreover, Citadel Lc has 0% invested in Delcath Systems, Inc. (NASDAQ:DCTH) for 157,333 shares. Ladenburg Thalmann Fincl Services holds 0% or 1,456 shares in its portfolio. Royal Bank Of Canada has invested 0% of its portfolio in Delcath Systems, Inc. (NASDAQ:DCTH). Deutsche Commercial Bank Ag accumulated 5 shares or 0% of the stock. Goldman Sachs Gru accumulated 0% or 15,211 shares. Geode Mgmt Lc holds 0% or 39,792 shares in its portfolio. Kcg Hldgs has invested 0% of its portfolio in Delcath Systems, Inc. (NASDAQ:DCTH). Creative Planning, a Kansas-based fund reported 307 shares. Blackrock Institutional Na has 531,871 shares for 0% of their US portfolio. Wells Fargo & Mn last reported 157 shares in the company. Renaissance Techs Ltd Llc holds 0% or 754,998 shares in its portfolio. Group One Trading Ltd Partnership reported 5,123 shares or 0% of all its holdings. Private Advisor Gp Llc reported 206,670 shares or 0% of all its holdings. Blackrock Fund Advisors accumulated 4,024 shares or 0% of the stock.

More notable recent Delcath Systems, Inc. (NASDAQ:DCTH) news were published by: which released: “Delcath Announces Proposed Public Offering of Common Stock and Warrants” on September 29, 2016, also with their article: “Delcath Systems Inc.” published on December 22, 2009, published: “Delcath Sponsors Ocular Melanoma Foundation Patient Retreat” on September 19, 2016. More interesting news about Delcath Systems, Inc. (NASDAQ:DCTH) were released by: and their article: “Delcath To Present At The 2016 Aegis Growth Conference” published on September 12, 2016 as well as‘s news article titled: “Delcath prices stock offering at $3; shares off 21%” with publication date: September 30, 2016.

DCTH Company Profile

Delcath Systems, Inc., incorporated on August 5, 1988, is a late-stage clinical development firm with early commercial activity in Europe focused on cancers of the liver. The Firm is a specialty pharmaceutical and medical device firm developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS). The Company’s system delivers and filters melphalan hydrochloride, which is marketed as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan (CHEMOSAT). The Company’s focus is on the execution of the clinical development program (CDP) in ocular melanoma liver metastases (mOM), intrahepatic cholangiocarncinoma (ICC), hepatocellular carcinoma (HCC or primary liver) and other cancers that are metastatic to the liver.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Leave a Comment